三药联用治疗中重度慢性阻塞性肺疾病非急性期发作期临床疗效对比

Clinical efficacy of montelukast combined with seretide based on ambroxol in the treatment of moderate to severe chronic obstructive pulmonary diseases in non-acute episodes

目的评价氨溴索基础上采用孟鲁司特联合舒利迭治疗中重度慢性阻塞性肺疾病非急性发作期的临床疗效。方法将60例中重度慢性阻塞性肺疾病非急性期患者随机分为观察组和对照组,其中对照组30例采用氨溴索治疗,观察组在对照组治疗的基础上家用孟鲁司特联合舒利迭治疗,观察并比较两组患者临床疗效、住院情况及肺功能指标变化情况。结果观察组总有效率为96.7%,对照组总有效率为83.3%,两组比较差异有统计学意义(P<0.05),观察组咳嗽等临床症状消失的时间及住院时间与对照组相比差异有统计学意义(P<0.05),观察组治疗后FEV1及FEV1/FVC值较治疗前明显改善,与对照组治疗后值相比差异有统计学意义(P<0.05)。结论氨溴索基础上采用孟鲁司特联合舒利迭治疗中重度慢性阻塞性肺疾病非急性期发作期疗效好,值得在临床上予以推广。

Objective To evaluate clinical efficacy of montelukast combined with seretide based on ambroxol in the treatment of moderate to severe chronic obstructive pulmonary diseases in non-acute episodes. Methods From June 2010 to June 2013, 60 patients with moderate to severe chronic obstructive pulmonary disease in acute non-randomly were divided into observation group and control group, control group using ambroxol treatment, observation group were based on the combined household seretide montelukast treatment groups were observed and compared the clinical efficacy, patient conditions and changes in lung function. Results The total effective rate was 96.7%in the control group, the total effective rate was 83.3%, in observation group the difference was statistically significant （P〈0.05）, the observation group cough and other clinical symptoms of the time and length of stay compared with the control group difference was statistically significant, P〈0.05;observation group after treatment, FEV1 and FEV1/FVC values significantly improved compared with before treatment, the difference was statistically significant compared with control group after treatment （P〈0.05）. Conclusion Ambroxol based on the use of montelukast combined with seretide has a good effect in the treatment of moderate to severe chronic obstructive pulmonary disease in non-acute episodes, so it is worthy of clinical promotion.